Pfizer (PFE) Common Equity (2009 - 2026)
Pfizer (PFE) posted quarterly Common Equity of $90.1 billion for Q1 2026, down 0.59% year-over-year from $90.6 billion in Q1 2025, and up 3.83% quarter-over-quarter from $86.8 billion in Q4 2025.
Pfizer (PFE) Common Equity (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Common Equity for 18 consecutive years, with $90.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 0.59% year-over-year to $90.1 billion; the TTM figure through Mar 2026 stood at $90.1 billion (down 0.59% YoY), while the FY2025 annual figure was $86.8 billion, down 1.95% from the prior year.
- Common Equity improved to $90.1 billion in Q1 2026 per PFE's latest filing, from $86.8 billion in the prior quarter.
- Across five years, Common Equity topped out at $101.2 billion in Q2 2023 and bottomed at $18.7 billion in Q3 2022.
- Historically, Common Equity has averaged $82.7 billion across 5 years, with a median of $89.3 billion in 2023.
- Annual changes were most pronounced in 2022 — Common Equity sank 48.08% — and 2024, when it surged 346.73%.
- Pfizer's Common Equity stood at $95.9 billion in 2022, then dropped by 6.91% to $89.3 billion in 2023, then fell by 0.89% to $88.5 billion in 2024, then dropped by 1.95% to $86.8 billion in 2025, then rose by 3.83% to $90.1 billion in 2026.
- Business Quant data shows PFE's Common Equity at $90.1 billion in Q1 2026, $86.8 billion in Q4 2025, and $92.8 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 106.07 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 23.05 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 80.86 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 85.49 Bn |
| Mar 29, 2026 | 90.10 Bn |
| Dec 31, 2025 | 86.78 Bn |
| Sep 28, 2025 | 92.80 Bn |
| Jun 29, 2025 | 89.01 Bn |
| Mar 30, 2025 | 90.64 Bn |
| Dec 31, 2024 | 88.50 Bn |
| Sep 29, 2024 | 92.56 Bn |
| Jun 30, 2024 | 87.98 Bn |
| Mar 31, 2024 | 92.56 Bn |
| Dec 31, 2023 | 89.29 Bn |
| Sep 30, 2023 | 20.72 Bn |
| Jul 2, 2023 | 99.29 Bn |
| Apr 2, 2023 | 101.24 Bn |
| Dec 31, 2022 | 95.92 Bn |
| Sep 30, 2022 | 18.68 Bn |
| Jul 3, 2022 | 87.47 Bn |
| Apr 3, 2022 | 82.69 Bn |
| Dec 31, 2021 | 77.46 Bn |
| Oct 3, 2021 | 35.98 Bn |